Bial-Portela, Neurocrine Biosciences deal

Bial-Portela granted Neurocrine Biosciences exclusive, North American rights to Parkinson's disease drug Ongentys opicapone (ONO-2370). Bial-Portela will receive $30 million up front and is eligible for up to $115 million in milestones, plus 37% of net sales in exchange for manufacturing and supplying the drug. Ongentys is approved in the EU as an adjunctive therapy to levodopa/dopa decarboxylase (DDC; AADC) inhibitors in adults with PD and end-of-dose motor fluctuations who cannot be stabilized on those combinations.

On a conference call, Neurocrine said it plans to meet with FDA this year to discuss a path to approval. Since Bial-Portela conducted its entire development program for Ongentys in the EU, Neurocrine will ask FDA whether additional data need to be generated...